Recent developments include Daré's Q2 2026 financial results reporting a net loss and revenue details, ongoing pivotal clinical trial updates, and progress in commercialization of DARE to PLAY Sildenafil Cream. The company faces Nasdaq listing compliance challenges with a scheduled hearing.

• Daré reported a Q2 2026 net loss of approximately $2.98 million and basic and diluted EPS of -$0.20, with cash and equivalents of about $12.6 million as of June 30, 2026 [N1][S2].
• The company commenced pharmacy dispensing and revenue recording for DARE to PLAY Sildenafil Cream in Q2 2026, a topical treatment for female sexual arousal disorder marketed under Section 503B compounding [N1][S1].
• FDA approved a protocol amendment for the Ovaprene Phase 3 clinical study reducing the required number of completers, but cautioned that the data may be insufficient to support approval, highlighting regulatory risk [S2].
• Daré received a delisting determination letter from Nasdaq in July 2026 due to stockholders' equity below $2.5 million, with a hearing scheduled for late August 2026 [S2].
• The company continues to leverage strategic partnerships for manufacturing, telehealth, and pharmacy services to support commercialization without building internal sales infrastructure [S1].

Daré's approach to women's health addresses significant unmet medical needs with a diversified portfolio spanning contraception, sexual health, and menopause. The dual-path strategy allows earlier market entry via Section 503B compounded drugs while pursuing FDA approvals, potentially expanding access and revenue streams. The launch of DARE to PLAY Sildenafil Cream marks a commercial milestone, supported by telehealth and pharmacy partnerships. Ongoing pivotal trials such as Ovaprene's Phase 3 study could validate novel contraceptive options. Strategic collaborations and non-dilutive funding enhance development capabilities and financial sustainability. The company's focus on evidence-based, clinically credible products may strengthen brand recognition and provider engagement in a growing women's health market.

Daré faces regulatory and operational risks including FDA concerns about the sufficiency of clinical data from its Ovaprene Phase 3 trial, which may require additional studies or delay approval. The company has reported consistent net losses and maintains liquidity ratios near parity, indicating potential financial constraints. Nasdaq listing compliance issues pose a risk of delisting, which could impair capital raising and investor confidence. The reliance on third-party manufacturing, telehealth, and pharmacy partners for commercialization may limit control over market execution. Additionally, compounded drug products under Section 503B are not FDA-approved and lack insurance reimbursement, potentially limiting market adoption. Competitive pressures and the need for continued non-dilutive funding add to execution challenges.

Daré's moat derives from its focused expertise in women's health biotech, leveraging proprietary formulations and a dual-path regulatory strategy that combines traditional FDA approval with Section 503B compounding to accelerate market access. The company's portfolio includes first-in-category or novel products addressing underserved indications, supported by clinical data and cGMP manufacturing partnerships. Strategic collaborations with established commercial partners, telehealth platforms, and pharmacies enable efficient commercialization without the overhead of building internal sales and marketing infrastructure. Additionally, non-dilutive funding sources and royalty monetization agreements provide financial flexibility. However, the company's reliance on external partners and regulatory approvals introduces execution risks.

• Regulatory Approval Risks: FDA has expressed concerns about the adequacy of the Ovaprene Phase 3 clinical trial design and data sufficiency, which may require additional enrollment or studies, potentially delaying or preventing approval [S2].
• Financial and Liquidity Risks: The company reported a net loss of $2.98 million for Q2 2026 and has liquidity ratios near 1.0, indicating tight working capital. Ongoing losses and limited cash reserves may constrain operations [S2].
• Nasdaq Listing Compliance Risk: Daré received a delisting determination letter due to stockholders' equity below required thresholds, with a hearing scheduled in August 2026. Delisting could impair capital raising and market liquidity [S2].
• Commercialization and Market Access Risks: Reliance on third-party manufacturing, telehealth, and pharmacy partners limits direct control over sales and distribution. Section 503B compounded products are not FDA-approved and lack insurance coverage, which may limit patient access and revenue potential [S1].
• Competitive and Market Risks: The women's health biotech space is competitive with evolving regulatory and market dynamics. The company must successfully differentiate its products and navigate reimbursement challenges.

• Daré Bioscience, Inc. is a health biotech company focused exclusively on women's health, aiming to close gaps between scientific advances and real-world solutions across areas including contraception, sexual health, pelvic pain, fertility, vaginal health, infectious disease, and menopause [S1].
• The company pursues a dual-path commercialization strategy: traditional FDA approval and earlier market access via Section 503B compounding outsourcing facilities, allowing compounded drug products without patient-specific prescriptions [S1].
• Daré's first FDA-approved product is XACIATO (clindamycin phosphate vaginal gel 2%), approved in December 2021 for bacterial vaginosis, with exclusive worldwide rights licensed to Organon for commercialization [S1].
• Daré monetized royalties from XACIATO sales by selling rights to XOMA, receiving upfront funding and sharing royalties after XOMA's return is met [S1].
• The company has a pipeline including Ovaprene, a hormone-free monthly intravaginal contraceptive in pivotal Phase 3; Sildenafil Cream 3.6% for female sexual arousal disorder; DARE-HRT1, an intravaginal ring delivering menopausal hormone therapy; and DARE-HPV, a vaginal insert for clearance of high-risk HPV infection [S1].
• DARE to PLAY Sildenafil Cream is the first product marketed under Section 503B compounding, a topical sildenafil cream for female sexual arousal disorder, manufactured by Bravado Pharmaceuticals and dispensed via Medvantx, available on a cash-pay basis without insurance coverage [S1].
• The company launched commercialization of DARE to PLAY in Q2 2026, with pre-fulfillment and telehealth prescription services through the DARE Health Hub platform [S1].
• Daré does not have its own sales or marketing infrastructure but relies on third-party manufacturing, telehealth, and pharmacy partnerships for commercialization [S1].
• The company pursues non-dilutive funding sources including U.S. government grants to support R&D and clinical development [S1].
• Daré reported Q2 2026 financial results with a net loss of approximately $2.98 million and basic and diluted EPS of -$0.20, with cash and equivalents of about $12.6 million as of June 30, 2026 [S2].
• Liquidity ratios as of June 30, 2026, include a current ratio of 0.99 and a cash ratio of 0.75, indicating near parity of current assets and liabilities [S2].
• The company faces Nasdaq listing compliance challenges due to stockholders' equity below $2.5 million and received a delisting determination letter in July 2026, with a hearing scheduled for late August 2026 [S2].
• The pivotal Phase 3 clinical study of Ovaprene is ongoing under an Investigational Device Exemption, with a recent FDA-approved protocol amendment reducing the required number of completers but with FDA cautioning that the data may be insufficient to support approval [S2].
• Daré engages in strategic collaborations and licensing agreements to fund development and commercialization, including with Organon, Bravado Pharmaceuticals, Medvantx, and XOMA [S1].
• Recent news reports cover quarterly earnings calls and financial results, including Q2 2026 loss and revenue details, and product commercialization updates [N1][N3][N4][N6].